

# Role of psychotropics in suicide prevention

BCNBP Dutch Regional Meeting - Ghent 21/10/2016

Dr Kate Saunders

Clinical Lecturer & Consultant Psychiatrist

Centre for Suicide Research


University of Oxford

#### Overview

- Background & methodological issues
- Lithium
- Anticonvulsants
- Antipsychotics
- Antidepressants
- Ketamine
- Minor tranquilisers
- BPD

# Background


- Suicide rare but devastating event
  - 11/100,000 /year internationally but rates vary considerably
- In the top three causes of death in those aged 15-44 (WHO)
- Suicide is strongly associated with mental disorder
  - Major affective disorders predominate
  - SMR = 10-20x general population



# Methodological challenges

- Large numbers
- Ethics of recruiting suicidal patients
- Role of concomitant factors e.g substance misuse
- Nomenclature
- Need to control for frequency of clinical contact
- Commercial considerations

Evidence largely observational or from post hoc analyses



Bottle cap and label from 1930s era.








Nothing does it like Seven-Up!

#### Lithium

Rx for bipolar disorder Augmentation in UD

#### Meta analysis of RCTs

Cipriani 2013 BMJ



# Suicide attempts

- Registry based study
- 826 hospitalised bipolar patients
- Lithium
  - Lower risk of suicide attempts (non significant)
  - Lower risk of suicide (univariate RR=0.39, p=0.03, cox HR=0.37, p=0.02)
  - Decreased all cause mortality by 49%

Journal of Affective Disorders 183 (2015) 159-165



#### Contents lists available at ScienceDirect

#### Journal of Affective Disorders



journal homepage: www.elsevier.com/locate/jad

esearch report

Lithium is associated with decrease in all-cause and suicide mortality in high-risk bipolar patients: A nationwide registry-based prospective cohort study




Elena Toffol <sup>a.e</sup>, Taina Hätönen <sup>b.c</sup>, Antti Tanskanen <sup>d</sup>, Jouko Lönnqvist <sup>a.c</sup>, Kristian Wahlbeck <sup>a.e</sup>, Grigori Joffe <sup>f</sup>, Jari Tiihonen <sup>d</sup>, Jari Haukka <sup>a.g</sup>, Timo Partonen <sup>a</sup>

#### **Original Investigation**

#### Self-harm, Unintentional Injury, and Suicide in Bipolar Disorder During Maintenance Mood Stabilizer Treatment A UK Population-Based Electronic Health Records Study

Joseph F. Hayes, MSc, MBChB; AlexandraPitman, PhD; Louise Marston, PhD; Kate Walters, PhD; John R. Geddes, MD; Michael King, PhD; David P. J. Osborn, PhD



Shown are unadjusted Kaplan-Meier estimates of cumulative self-harm, with shaded areas showing 95% Cls.



Studies on the potential anti-suicidal effects of lithium as a trace element in drinking water

Year	Author	Measurement	Number of samples	Results
2009/Japan	Ohgami et al.	Li level in drinking water	18 municipalities	Standardized mortality ratio (SMR) negatively correlated with Li levels
2011/UK	Kabacs et al.	Li level in drinking (tap) water	47 samples from 47 subdivisions	No association between lithium levels in drinking (tap) water and mortality from suicide in the East of England
2011/Austria	Kapusta et al.	Li level in drinking water	6460 lithium measures of 99 Austrian districts	Suicide rate, SMR inversely associated with Li levels
2013/Greece	Giotakus et al.	Li level in drinking water	149 water samples from 34 prefectures	Tendency for lower suicide rates in the prefectures with high levels of lithium in drinking water
2013/USA	Blüml et al.	Li level in public water	3123 lithium water samples, 226 counties	Higher lithium levels in the public drinking water were associated with lower suicide rates
2015/Italy	Vita et al.	Li level in drinking water	Review	Higher levels in drinking water may be associated with reduced risk of suicide in the general population

Li lithium

#### Lithium – mechanism of action

- Unknown
- Greater magnitude of effect on suicidality than depressive Sx
   BUT
- Narrow therapeutic window
- Significant side effects
- Highly toxic in overdose

#### Anticonvulsants

- Rates of suicide may be higher in those on sodium valproate (Goodwin 2003, Toffol 2015)
  - Confounding by indication
  - Increased risk associated with stopping lithium to switch to valproate
- No difference between anticonvulsants & lithium reported (Yerevanian 2003)

- Danish data suggest protective effect if compliant (Smith 2009)
  - Large sample
  - Healthcare records
  - Consistent collection of prescriptions associated with reduction in suicides
  - Similar reduction for lithium


# Antipsychotics

- In RCTs little difference found when compared to placebo (Khan 2001)
  - All FDA registered trials of FGA or SGA v placebo
  - May simply reflect sample characteristics of those entering RCTs
- Retrospective database study suggested better compliance reduced risk
- Available data supports the protective effect of Clozapine
  - Those switched to clozapine demonstrated a reduction in suicide attempts (Meltzer 1995)
    - No follow-up data reported
  - Clozaril National Register (62,072 patients) current users had lower mortality rate than past users
    - No control group
    - Discontinuation associated with poorer clinical outcome

Intersept (International Suicide Prevention

Trial)

- Olanzapine v Clozapine
- Randomised multicentre trial
- Schizophrenia / Schizoaffective
- 980 patients
- 18 months
- Fewer suicides but small N



Kaplan-Meier estimates of the probability of a suicide attempt or hospitalization to prevent suicide.


## Clozapine - mechanism

- Closer follow-up due to monitoring for agranulocytosis
- Better symptomatic control
- Unique and complex pharmacology
  - Simultaneous modulation of multiple neurotransmitters
  - Hormones eg cortisol
  - Intracellular systems e.g NMDA receptor expression


# Antidepressants


Controversial issue

- Ongoing debate especially in young people
  - Suicide 3rd leading cause of death in young people
  - 90% of depressive symptoms untreated at time of death (Leon 2004)




	No of events/total					
Study	Drugs	Placebo	Peto odds ratio fixed (95% CI)	Weight (%)	Peto odds ratio fixed (95% CI)	
Adults			lixed (95 % Ci)	( 10)	lixed (95 % Ci)	
Trial 04	1/196	0/99		1.0	4.50 (0.07 to 285.95)	
Trial 05	1/123	2/122		3.5	0.51 (0.05 to 4.91)	
Trial 06	1/128	3/139		4.6	0.39 (0.05 to 2.84)	
Trial 07	2/136	0/142	1	2.3	7.78 (0.48 to 125.09)	
Trial 09	2/264	0/89		1.8	3.82 (0.16 to 93.42)	
Trial 10	0/89	2/88		2.3	0.13 (0.01 to 2.13)	
Trial 11	0/390	1/126	•	0.9	0.02 (0.00 to 1.60)	
Trial 16	1/227	0/231		1.2	7.52 (0.15 to 379.06)	
Trial 30	1/160	1/162		2.3	1.01 (0.06 to 16.26)	
Trial 31	1/151	0/156		1.2	7.64 (0.15 to 385.12)	
Trial 32	1/365	1/186		2.1	0.48 (0.03 to 9.08)	
Trial 38	1/151	0/37	-	0.7	3.47 (0.03 to 480.43)	
Trial 39	0/129	2/129		2.3	0.13 (0.01 to 2.16)	
Trial 44	1/100	0/108	-	1.2	8.00 (0.16 to 404.57)	
Trial 45	1/86	0/83		1.2	7.14 (0.14 to 359.84)	
Trial 49	1/135	0/69		1.0	4.53 (0.07 to 285.39)	
Trial 53 and 54	1/241	0/84		0.9	3.85 (0.04 to 338.83)	
Trial 58	1/132	0/45		0.9	3.82 (0.04 to 344.50)	
Trial 63	1/72	0/76		1.2	7.81 (0.15 to 394.22)	
Trial 64	2/157	0/152		2.3	7.20 (0.45 to 115.73)	
Trial 67	0/238	1/80	-	0.9	0.02 (0.00 to 1.72)	
Trial 68	1/100	2/104		3.5	0.53 (0.05 to 5.16)	
Subtotal (95% CI)	21/3770	15/2507	-	39.3	1.09 (0.55 to 2.14)	
Test for heterogen P=0.31,   <sup>2</sup> =11%	eity: χ <sup>2</sup> =23	.60, df=21,				
Test for overall effe	ect: z=0.24	, P=0.81				






Simon 2006 BMJ

# Impact of safety warnings






**USA** 




-90







Netherlands




2002

2004

2005

2000

BMJ 2014
Healthcare claims data
11 health plans un the
US mental health
research network
Adolescents (10-17)





#### Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose

Keith Hawton, Helen Bergen, Sue Simkin, Jayne Cooper, Keith Waters, David Gunnell and Navneet Kapur

**Table 2** Fatal toxicity: rate ratios and relative toxicity indices for individual antidepressants based on rates of death (suicide and undetermined intent) in England and Wales, and prescription rates in the UK

	Both ge	Both genders		Males		Females	
	Rate ratio (95% CI)	Relative toxicity index <sup>a</sup>	Rate ratio (95% CI)	Relative toxicity index <sup>a</sup>	Rate ratio (95% CI)	Relative toxicity index <sup>a</sup>	
TCAs							
Amitriptyline	11.4 (10.3–12.6)	1.0	20.3 (17.7-23.2)	1.0	7.5 (6.5–8.7)	1.0	
Clomipramine	14.1 (10.0 –19.3)	1.2	15.9 (8.4–27.1)	0.8	13.3 (8.7–19.5)	1.8	
Dosulepin	36.3 (33.4–39.3)	3.2	70.5 (62.9–78.8)	3.5	23.3 (20.6–26.2)	3.1	
Doxepin	28.1 (17.6-42.6)	2.5	60.1 (32.0-102.7)	3.0	15.9 (7.3-20.1)	2.1	
Imipramine	12.4 (8.1-18.4)	1.1	17.0 (8.5–30.4)	0.8	10.2 (5.6-17.2)	1.4	
Nortriptyline	9.9 (3.2-23.2)	0.9	0	_	13.3 (4.3–31.0)	1.8	
Trimipramine	15.0 (8.0-25.6)	1.3	35.1 (15.2-69.2)	1.7	7.8 (2.5–18.1)	1.0	
All seven TCAs	18.8 (17.7–20.0)	1.7	33.7 (31.0–36.5)	1.7	12.6 (11.6–13.8)	1.7	
SNRI: venlafaxine	5.3 (4.2–6.6)	0.46	8.7 (6.4–1.6)	0.43	3.5 (2.5–4.9)	0.47	
Nassa: mirtazapine	3.6 (2.1–5.7)	0.32	4.1 (1.8–8.1)	0.20	3.3 (1.6–6.0)	0.44	
SSRIs							
Citalopram	1.7 (1.3-2.3)	0.15	3.3 (2.2-4.7)	0.16	1.0 (0.6-1.6)	0.14	
Fluoxetine	0.5 (0.3-0.9)	0.05	0.6 (0.2-1.3)	0.03	0.5 (0.3-1.0)	0.07	
Fluvoxamine	0	0	0	0	0	0	
Paroxetine	0.5 (0.2-0.9)	0.04	1.1 (0.4–2.2)	0.05	0.2 (0.05-0.6)	0.03	
Sertraline	0.7 (0.3–1.3)	0.06	1.1 (0.3–2.7)	0.05	0.5 (0.1–1.2)	0.06	
All five SSRIs	0.9 (0.7-1.1)	0.08	1.6 (1.2–2.1)	0.08	0.6 (0.4-0.8)	0.08	

TCAs, tricyclic antidepressants; SNRI, serotonin and noradrenaline reuptake inhibitor; NaSSA, noradrenergic and specific serotonergic antidepressant; SSRIs, selective serotonin reuptake inhibitors.

a. Index of toxicity relative to amitriptyline.

#### Ketamine

- Widely used in anaesthesia
- Misused
- NMDA receptor antagonist
- Sub-therapeutic doses
- 6 treatment protocols of iv 0.5mg/kg (3 Rx) then 0.75mg/kg
- Emergent evidence base for treatment resistant depression
- Nasal administration currently being trialled.
- Side effects: dry mouth, tachycardia, hypertension, restlessness, visual disturbance, dissociation (usually short lived)






Fig. 2 Global ketamine's efficacy on depressive symptomatology in non-ECT and ECT studies. All depression assessments were made 24 h after administration in non-ECT studies


# Single infusion (Murrough et al 2015)








# Ionescu et al 2016 J Clin Psych

- Open label study
- Intravenous ketamine
- 14 patients
- MDD with suicidal thoughts









#### Mechanism

- Appears to alter a number of domains associated with suicidality
  - Anxiety
  - Anhedonia
  - Rumination resting state DMN network data from healthy controls (DMN disruption associated with rumination)

# Minor tranquilisers

- Epidemiological studies: increased risk of suicide
  - Poorly controlled for
    - Depression
    - Other psychiatric disorders associated with insomnia
- Suicides associated with single agent hypnotic overdoses

**BUT** 

Insomnia is associated with suicidality

#### **ECT**

- No randomised evidence
- Expert consensus supports
- Limited role
  - Cost
  - Availability
  - Associated stigma
  - Involved process

# Pharmacotherapy in borderline PD

- Flupenthixol (Montgomery & Montgomery 1982)
  - Reduction in self harm
  - Never replicated
- Paroxetine (Verkes 1998)
  - No difference in repetition of self-harm
  - In those with fewer than 5 past episode more effective
- Fluoxetine (Coccaro 1997)
  - May reduce aggression

# Other possible compounds

# Tiny doses of opioid could be first fast anti-suicide drug



New scientist Feb 2016

- Double blind placebo controlled trial
- Suicidal patients(N=40)
- No hx of substance misuse
- sublingual administration
- 0.1 mg daily for 4 weeks
- in addition to current treatments
- Significant decrease in suicidal ideation

Yovel 2016 AJP

#### Conclusion

- Good medication concordance is protective
- Lithium consistent protective effect
  - Largely limited to bipolar disorder
  - Side effect profile
- Relationship between antidepressants and suicidality remains contested
- Clozapine
- Ketamine
  - Promising findings
  - Duration of treatment effect unknown
  - May provide us with a tool to explore underlying biological mechanisms
  - IV administration limits use currently
- Buprenorphine

# QUESTIONS